Thoughts from Roger Longman on Arena Bioworks and new models for creating differentiated innovations for patients and the healthcare system. TLDR: An interesting BUT expensive experiment.
read full article ›Coming out of the overwhelming focus on obesity drugs during the JPMorgan Chase & Co. Healthcare Conference, Eli Lilly and Company and Novo Nordisk have both taken beginning of the year price increases.
read full article ›There was much discussion at hashtag#JPM2024 on the travails of cell therapy companies. Real Endpoints co-founder Roger Longman has been thinking about the challenges and opportunities.
read full article ›JPM 2024 is officially in the books! Panels, presentations, receptions, meetings - always an amazingly inspiring place to connect, learn and share together as an industry with friends, colleagues and clients.
read full article ›